论文部分内容阅读
作者对44例慢性粒细胞白血病慢性期接受同种骨髓移植术后的患者进行了前瞻性肺功能变化的研究。术前全部患者均接受单剂量红比霉素60mg/M~2环磷酰胺60mg/kg×2,以及分程全身照射,总剂量分别为10Gy(21例)和12Gy(23例)。其中29例采用的骨髓经单克隆抗体Campath-1消除T细胞。术后每3个月测定用力肺活量(FVC),肺活量(VC),单次呼吸一氧化碳(氵弥)散系数(Kco),一氧化碳(氵弥)散量(DLCO),最大吸气时肺泡容量(V_A)并对存活12个月以上的34例,存活24个月以上的16例作了多项回归分析。使用无T细胞骨髓的患者发生急性(6/29例)和慢性(11/24例)移植物抗宿主病的发病率较未清除T细胞骨髓者(分别为13/15和5/10例)为低。骨髓移植术前肺功能测定基本正常。34例存活和10例死亡者,其中8例吸烟者与26例非吸烟者,两者比较无差异。术后6、12个月各项肺功能显著减退,以6个月时下降最著,其中DLCO从术前的89%下降到66%(6个月)和70%(12个月),然后逐步恢复。发生急性移植物抗宿主病对FEV_1和V_A有明显影响(P分别<0.03和0.05),慢性移植物抗宿主病可
Forty-four patients with chronic myeloid leukemia who underwent allogeneic bone marrow transplantation were prospectively studied for changes in lung function. All patients received a single dose of 60 mg / kg cyclophosphamide 60 mg / kg × 2, and a total dose of 10 Gy (21 cases) and 12 Gy (23 cases), respectively. 29 of the bone marrow used by the monoclonal antibody Campath-1 eliminate T cells. FVC, VC, Kco, DLCO and alveolar volume at maximum inspiratory pressure were measured every 3 months after operation. V_A) and survival of more than 12 months in 34 cases, survival of more than 24 months of 16 cases made a number of regression analysis. The incidence of acute (6/29 cases) and chronic (11/24 cases) GVHD in patients without T-cell marrow compared with those without T-cell marrow (13/15 and 5/10, respectively) Low. Bone marrow transplantation preoperative pulmonary function tests were normal. 34 survived and 10 died, including 8 smokers and 26 non-smokers, the two were no difference. Lung function decreased significantly at 6 and 12 months after operation, with the most significant decrease at 6 months, with DLCO decreasing from 89% preoperatively to 66% (6 months) and 70% (12 months) Gradual recovery. Acute graft versus host disease had a significant effect on FEV_1 and V_A (P <0.03 and 0.05, respectively), and chronic graft versus host disease